Valeant On Upswing With Walgreens Deal
This article was originally published in Scrip
You may also be interested in...
The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.
The plagued specialty pharma has been rumored to have at least one suitor, but analysts are skeptical and expect multiple divestitures will be required if the company is going to gain back some of its losses.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.